To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

A Relative Bioavailability Study of Metformin HCL 500 mg XR Tablets Under Fasting Conditions

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00882882

Enrollment

Registered

2009-04-17

Start date

2001-06-30

Completion date

2001-06-30

Last updated

2017-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II Diabetes

Brief summary

To demonstrate the relative bioavailability of Metformin HCl 500 mg XR tablets under fasting conditions.

Interventions

DRUGMetformin HCL 500 mg Extended-Release Tablets, Geneva PTC

DRUGGLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 49 Years

Healthy volunteers

Yes

Inclusion criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

* Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.

Design outcomes

Primary

Measure	Time frame
Bioequivalence based on AUC and Cmax	23 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026